Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Long-Term Investments (2016 - 2025)

Regenxbio (RGNX) has 12 years of Long-Term Investments data on record, last reported at $10.8 million in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 5.95% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, up 5.95%, while the annual FY2025 figure was $10.8 million, 5.95% up from the prior year.
  • Long-Term Investments reached $10.8 million in Q4 2025 per RGNX's latest filing, down from $27.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $391.9 million in Q4 2021 and bottomed at $4.9 million in Q1 2025.
  • Average Long-Term Investments over 5 years is $131.9 million, with a median of $79.0 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: soared 737.25% in 2021, then plummeted 88.38% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $391.9 million in 2021, then tumbled by 48.82% to $200.6 million in 2022, then crashed by 80.62% to $38.9 million in 2023, then plummeted by 73.81% to $10.2 million in 2024, then increased by 5.95% to $10.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $10.8 million in Q4 2025, $27.8 million in Q3 2025, and $40.3 million in Q2 2025.